Merck & Co. Inc., known as MSD outside the United States and Canada, has announced that it will present new data from its HIV prevention and treatment research pipeline at the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda, from July 13-17, 2025. The company will share findings from its HIV clinical development programs, including Phase 2 data on the safety and pharmacokinetics of MK-8527, an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) developed for pre-exposure prophylaxis (PrEP). Additionally, results from three Phase 3 trials will be presented, examining the impact of a once-weekly oral combination treatment of islatravir and ulonivirine, which is progressing in clinical development. The presentations aim to offer insights into new therapeutic options for individuals affected by HIV.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.